The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F19%3A00070835" target="_blank" >RIV/65269705:_____/19:00070835 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/19:00110102

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S2211034819300938" target="_blank" >https://www.sciencedirect.com/science/article/pii/S2211034819300938</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.msard.2019.02.019" target="_blank" >10.1016/j.msard.2019.02.019</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings

Popis výsledku v původním jazyce

Background: Natalizumab-related progressive multifocal leukoencephalopathy (PML) is associated with the presence of anti-John Cunningham virus (JCV) antibodies. The aim of this investigation was to evaluate the long-term stability of anti-JCV antibody serum levels and their relation to various demographic, clinical and radiological characteristics in patients suffering from multiple sclerosis (MS). Methods: Seventy-eight relapsing-remitting MS patients treated with natalizumab and evaluated for the presence of serum anti-JCV antibodies over a time period of 1-6 years (3-11 samples) were included in the study. Anti-JCV antibody levels and their changes were correlated with various demographic, clinical and radiological findings. Results: Median follow-up time was 43.5 months, with a median of 5.3 samples available per patient. At baseline, 46 (59%) of the patients were seropositive. During follow-up, anti-JCV antibody status changed from negative to positive or vice versa in 23% of patients. Baseline anti-JCV antibody index correlated positively with age (p = 0.03). Patients: with stable positive anti-JCV antibody index had more T2 hyperintensities (20.2 vs. 13.1; p &lt; 0.007) on cerebral magnetic resonance imaging (MRI) and were also older than the stable negative anti-JCV antibody index group of patients (45.2.vs. 40.3 years; p &lt; 0.01). No significant increase in T2 hyperintensities after seroconversion was revealed. Average duration from beginning of natalizumab therapy to seroconversion fit = 13) was 33 months. Annual seroconversion rate of anti-JCV antibody status was 6.5%. A baseline anti-JCV antibody index of &gt; 0.90 (tt = 33) predicted stable seropositivity (100%), while baseline anti-JCV antibody index &lt;0.20 did not predicted stable seronegativity (59%). PML was not diagnosed in any of the patients studied during the follow-up. Conclusions: A positive baseline anti-JCV antibody index of &gt; 0.90 predicts stable positive JCV serostatus, in contrast with a baseline anti-JCV antibody index of &lt;0.20, which remained negative in 59% of cases. Stable positive anti-JCV index patients have more MRI T2 hyperintensities and are older compared with stable negative anti-JCV index patients.

Název v anglickém jazyce

The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings

Popis výsledku anglicky

Background: Natalizumab-related progressive multifocal leukoencephalopathy (PML) is associated with the presence of anti-John Cunningham virus (JCV) antibodies. The aim of this investigation was to evaluate the long-term stability of anti-JCV antibody serum levels and their relation to various demographic, clinical and radiological characteristics in patients suffering from multiple sclerosis (MS). Methods: Seventy-eight relapsing-remitting MS patients treated with natalizumab and evaluated for the presence of serum anti-JCV antibodies over a time period of 1-6 years (3-11 samples) were included in the study. Anti-JCV antibody levels and their changes were correlated with various demographic, clinical and radiological findings. Results: Median follow-up time was 43.5 months, with a median of 5.3 samples available per patient. At baseline, 46 (59%) of the patients were seropositive. During follow-up, anti-JCV antibody status changed from negative to positive or vice versa in 23% of patients. Baseline anti-JCV antibody index correlated positively with age (p = 0.03). Patients: with stable positive anti-JCV antibody index had more T2 hyperintensities (20.2 vs. 13.1; p &lt; 0.007) on cerebral magnetic resonance imaging (MRI) and were also older than the stable negative anti-JCV antibody index group of patients (45.2.vs. 40.3 years; p &lt; 0.01). No significant increase in T2 hyperintensities after seroconversion was revealed. Average duration from beginning of natalizumab therapy to seroconversion fit = 13) was 33 months. Annual seroconversion rate of anti-JCV antibody status was 6.5%. A baseline anti-JCV antibody index of &gt; 0.90 (tt = 33) predicted stable seropositivity (100%), while baseline anti-JCV antibody index &lt;0.20 did not predicted stable seronegativity (59%). PML was not diagnosed in any of the patients studied during the follow-up. Conclusions: A positive baseline anti-JCV antibody index of &gt; 0.90 predicts stable positive JCV serostatus, in contrast with a baseline anti-JCV antibody index of &lt;0.20, which remained negative in 59% of cases. Stable positive anti-JCV index patients have more MRI T2 hyperintensities and are older compared with stable negative anti-JCV index patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Multiple Sclerosis and Related Disorders

ISSN

2211-0348

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

MAY 2019

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

187-191

Kód UT WoS článku

000464532100033

EID výsledku v databázi Scopus

2-s2.0-85061641612